A dehydroepiandrosterone sulfate (DHEA-S) test measures the most abundant circulating adrenal androgen. Because the adrenal glands produce nearly all DHEA-S, the result helps identify an adrenal contribution to acne, excess hair growth, irregular periods, early puberty, virilization, or an abnormal testosterone result. Mild elevation is common with PCOS, while a marked elevation—especially with symptoms progressing over months—can raise concern for an adrenal tumor or congenital adrenal hyperplasia. DHEA-S peaks in young adulthood and falls steadily with age, so an age-specific reference interval is essential. Low levels are usually nonspecific and can occur with aging, adrenal insufficiency, pituitary disease, glucocorticoid use, or chronic illness. The test is more stable through the day than unsulfated DHEA, but medicines, pregnancy, supplements, and assay methods still matter. DHEA-S should be interpreted with testosterone, androstenedione, 17-OHP, symptoms, and the reason for testing.
- DHEA-S is produced mainly by the adrenal glands and is a useful marker of adrenal androgen output.
- Mild elevation may occur with PCOS; a value several times the upper limit needs faster adrenal evaluation.
- Normal ranges change sharply with age and differ by sex and laboratory.
- DHEA supplements can raise results and may worsen acne, hair growth, or hormone-sensitive conditions.
- Low DHEA-S alone does not diagnose adrenal insufficiency and should be paired with cortisol and ACTH when suspected.
- Rapid virilization, severe weakness, vomiting, or low blood pressure requires prompt medical assessment.
Table of Contents
- What the DHEA-S Test Measures
- Why the Test Is Ordered
- Preparation, Timing, and the Testing Process
- Normal Range and How Results Are Interpreted
- What High DHEA-S Results Can Mean
- What Low DHEA-S Results Can Mean
- How Results Fit With Other Hormones and Tests
- Next Steps After the Result
What the DHEA-S Test Measures
DHEA is made from cholesterol in the adrenal cortex. An enzyme adds a sulfate group to create DHEA-S, a more stable form with a longer half-life. Peripheral tissues can convert these weak androgens into androstenedione, testosterone, and estrogens.
Unlike testosterone and androstenedione, DHEA-S has little direct ovarian production. That makes a disproportionately high DHEA-S result useful when clinicians are deciding whether androgen excess is mainly adrenal. It still cannot identify a tumor or enzyme defect without additional testing.
A hormone result is a measurement made under defined laboratory conditions, not a diagnosis by itself. The same concentration can carry different meaning at different ages, cycle stages, pregnancy stages, or times of day. Laboratories also use different analyzers, calibration systems, antibodies, and calculation methods. For that reason, the reference interval printed beside the result should take priority over a range copied from another report or website.
Levels rise during adrenarche, peak in the late teens or twenties, and decline over adulthood. A concentration that is normal at age 25 may be unusually high at age 65. Pediatric results require age- and puberty-stage intervals.
DHEA-S is often interpreted with an adrenal hormone panel when broader adrenal function is in question.
Why the Test Is Ordered
DHEA-S is ordered when symptoms suggest androgen excess, when the adrenal source needs assessment, or when adrenal function is already under investigation.
- Hirsutism, acne, scalp hair loss, or irregular ovulation.
- Rapid virilization, such as voice deepening or clitoromegaly.
- Premature pubic or underarm hair in a child.
- An elevated testosterone or androstenedione result that needs source clarification.
- Possible nonclassic CAH or an adrenal mass.
- Selected evaluation of adrenal insufficiency or pituitary disease, alongside more direct tests.
DHEA-S is not a routine fertility test and does not measure ovarian reserve or egg quality. It can matter when adrenal androgen excess disrupts ovulation. In men, it is rarely the first test for low libido or infertility because testosterone, LH, FSH, and semen analysis answer those questions more directly.
Interpretation starts with the reason the test was ordered. A clinician looking for an adrenal enzyme disorder uses different cutoffs and follow-up tests than a clinician evaluating irregular periods, infertility, menopausal symptoms, or androgen deficiency. The result should be read with symptoms, examination findings, age, reproductive stage, and related laboratory values rather than compared with one universal “optimal” number.
When irregular cycles and androgen symptoms occur together, a PCOS hormone panel can assess common and serious causes in a structured way.
Preparation, Timing, and the Testing Process
DHEA-S varies less over the day than cortisol or testosterone, but morning sampling is often used to standardize combined endocrine testing.
- Use the laboratory’s age- and sex-specific range and record the assay method.
- List DHEA, pregnenolone, testosterone products, glucocorticoids, hormonal contraception, and fertility medicines.
- Report pregnancy, major illness, or recent changes in hormone therapy.
- Follow fasting instructions if glucose, insulin, or lipids are being collected at the same visit.
- Do not stop prescribed steroids or supplements abruptly without clinical advice.
Menstrual-cycle timing is less critical than for progesterone, but an early-follicular sample may simplify a combined androgen workup. High-dose DHEA supplements can cause substantial elevations, and product content may differ from the label.
Before collection, provide a complete list of prescription medicines, over-the-counter products, supplements, contraceptives, fertility drugs, and hormone therapy. Do not stop prescribed treatment without instructions. Some products change hormone production, while others alter binding proteins or interfere with an immunoassay. High-dose biotin is a well-known source of interference in several hormone tests, although the direction and size of the error depend on the platform.
Acute illness can temporarily suppress or stimulate reproductive signaling. A test drawn during fever, major surgery, severe calorie restriction, or intense training may describe that temporary state rather than the person’s usual hormone function. When the clinical situation is stable and there is no urgent reason to test immediately, postponing or repeating the measurement can prevent an incorrect label.
Normal Range and How Results Are Interpreted
DHEA-S is commonly reported in mcg/dL or µmol/L. Reference intervals may vary several-fold across age groups, so the laboratory report is more useful than a single online range.
| Context | Expected influence | Interpretation |
|---|---|---|
| Childhood and puberty | Rises with adrenarche | Use age- and Tanner-stage ranges |
| Young adulthood | Usually highest lifetime concentrations | Upper limits are higher than in older adults |
| Later adulthood | Progressive decline | A modest number may still be normal |
| Pregnancy or hormone therapy | Can alter adrenal and binding physiology | Use condition-specific interpretation |
| DHEA supplementation | May markedly raise the level | Review exact product and dose |
Some clinicians use a value above roughly 700–800 mcg/dL in an adult woman as a reason to evaluate an adrenal tumor, but this is not a universal diagnostic cutoff. The degree above the laboratory upper limit, age, symptoms, and confirmation by a reliable method are more important.
A value close to a cutoff deserves more caution than a value that is clearly and repeatedly abnormal. Borderline results may move across the reference limit because of normal biologic variation, recent illness, sleep disruption, exercise, stress, or sample timing. Clinicians often repeat a test under better-controlled conditions before ordering imaging or beginning treatment. The repeat is most useful when the timing, medication list, and assay method are documented.
Trends can be useful when the same question is followed over time, but only when the measurements are reasonably comparable. A change between laboratories may reflect a method difference. A change after starting or stopping hormones may be expected. Record the laboratory, units, collection time, cycle day or pregnancy week, and relevant treatment so later results can be compared in context.
Comparing DHEA-S with an androstenedione test helps distinguish adrenal-predominant from mixed androgen excess.
What High DHEA-S Results Can Mean
High DHEA-S reflects increased adrenal androgen production, external DHEA exposure, or occasionally a laboratory problem.
- PCOS with an adrenal androgen contribution.
- Nonclassic or classic congenital adrenal hyperplasia.
- An adrenal androgen-producing adenoma or carcinoma.
- Premature adrenarche in a child.
- DHEA or prohormone supplements.
- Rare medication effects or assay interference.
PCOS usually causes a mild to moderate increase and develops gradually. A very high result or symptoms that progress rapidly should not be assumed to be PCOS. Repeat confirmation, testosterone, androstenedione, 17-OHP, and adrenal imaging may be needed.
In children, isolated early pubic hair can reflect benign premature adrenarche, but rapid growth, advanced bone age, genital enlargement, or other pubertal changes warrant a fuller endocrine evaluation.
Stop self-prescribed DHEA only after discussing the reason it was used, especially during fertility treatment. Marked confirmed elevation or rapid virilization should be referred promptly to endocrinology.
A CAH hormone panel is appropriate when 17-OHP, childhood history, or family history supports an adrenal enzyme disorder.
What Low DHEA-S Results Can Mean
Low DHEA-S is common with aging and has limited specificity. It may support adrenal or pituitary dysfunction only when the symptoms and more direct hormone tests point in the same direction.
- Normal age-related decline.
- Primary adrenal insufficiency.
- Low ACTH from pituitary or hypothalamic disease.
- Glucocorticoid treatment.
- Severe chronic illness, undernutrition, or physiologic stress.
- Individual variation within a healthy population.
DHEA-S is not recommended as the sole screening test for adrenal insufficiency. Morning cortisol, ACTH, electrolytes, and an ACTH stimulation test are more direct. Low levels also do not establish a need for DHEA replacement, and evidence for routine supplementation is limited.
In a person with fatigue alone, a low DHEA-S may be incidental. Symptoms such as weight loss, nausea, salt craving, low blood pressure, darkening skin, or recurrent low sodium make adrenal assessment more urgent.
Treat the underlying cause rather than targeting DHEA-S. Replacement decisions in documented adrenal insufficiency should be supervised because DHEA can cause acne, unwanted hair growth, mood changes, and uncertain long-term effects.
How Results Fit With Other Hormones and Tests
DHEA-S is most useful as part of an androgen and adrenal pattern.
| Pattern | Possible meaning | Follow-up |
|---|---|---|
| Mild high DHEA-S + irregular cycles | PCOS or functional adrenal excess | Assess testosterone, ovulation, and exclusion tests |
| Very high DHEA-S + rapid virilization | Adrenal tumor must be excluded | Confirm and arrange adrenal imaging |
| High DHEA-S + high 17-OHP | CAH pathway possible | ACTH stimulation and endocrine review |
| Normal DHEA-S + high testosterone | Ovarian or testicular source more likely | Evaluate gonadal causes |
| Low DHEA-S + low cortisol | Adrenal or central insufficiency possible | Measure ACTH and perform appropriate dynamic testing |
A normal DHEA-S does not exclude PCOS because androgen excess may be mainly ovarian. Likewise, a high result does not prove the adrenal gland is structurally abnormal; functional overproduction is more common than a tumor.
Next Steps After the Result
The follow-up plan should verify the magnitude of abnormality and determine whether the pattern is adrenal, ovarian, testicular, medication-related, or physiologic.
- Confirm age, sex, units, laboratory interval, medicines, and supplement exposure.
- Repeat an unexpected marked result with a reliable assay.
- Measure total testosterone, SHBG or free testosterone, androstenedione, and 17-OHP as indicated.
- Evaluate cortisol and ACTH when adrenal insufficiency is suspected.
- Use imaging only after the biochemical pattern and symptoms justify it.
- Address fertility, menstrual, or pubertal goals with the appropriate specialist.
For gradual mild hyperandrogenism, treatment can focus on the underlying PCOS pattern and symptoms. For a confirmed adrenal tumor or CAH, management is disease-specific. Serial testing is useful only when it will guide treatment or monitor a known condition.
Bring the actual report to the follow-up visit rather than only recalling that the level was “high” or “low.” The report shows units, the laboratory interval, specimen type, and sometimes the assay method. Ask whether the result needs confirmation, whether a related hormone should be measured at the same time, and what finding would change management.
A useful plan defines the next step and its timing. That may be no action, a repeat test, a dynamic stimulation or suppression test, ultrasound, semen analysis, genetic testing, or referral to endocrinology, reproductive endocrinology, urology, or maternal-fetal medicine. It should also identify symptoms that warrant earlier contact instead of waiting for the routine appointment.
Rapidly progressive symptoms deserve faster evaluation than a mild, stable laboratory abnormality. Examples include sudden virilization, severe headache with visual change, signs of adrenal crisis, heavy bleeding with dizziness, or concerning pregnancy symptoms. The laboratory number may guide the workup, but urgent decisions are driven by the whole clinical picture.
Treatment should address the confirmed cause and the person’s goals. Lowering or raising a laboratory value without establishing why it is abnormal can hide an important condition or create new problems. Hormone therapy can affect fertility, blood counts, liver function, clot risk, bone health, and pregnancy, so monitoring plans should be individualized.
Seek prompt care for rapid virilization, a new abdominal mass, or a child with quickly advancing puberty. Emergency care is needed for vomiting, dehydration, fainting, confusion, or severe low blood pressure that could indicate adrenal crisis.
When a repeat measurement is planned, try to reproduce the conditions that matter for this test. Use the same laboratory when practical, note the collection time, and record any change in medicines or reproductive stage. Consistency does not remove all biologic variation, but it makes a true trend easier to distinguish from noise.
Reference intervals describe a population selected by the laboratory; they do not define a treatment target for every person. A result inside the interval can still require attention when symptoms are strong or when another hormone shows a clear mismatch. Conversely, a small deviation may not represent disease when the timing or clinical setting explains it.
A laboratory result can answer only the question built into the test. It may show hormone concentration, but it cannot by itself prove ovulation quality, egg quality, sperm production, placental health, or the cause of a symptom. Those conclusions usually require a combination of history, examination, imaging, and other targeted tests.
When fertility is the concern, age, duration of trying to conceive, menstrual pattern, pregnancy history, semen findings, and tubal or uterine factors often affect the plan as much as a single hormone value. Testing both partners in parallel can prevent months of delay and reduce the chance that an incidental hormone result distracts from a more direct cause.
When symptoms are being monitored rather than fertility, define the outcome that treatment is meant to improve. Examples include restoration of periods, relief of hot flashes, reduction of unwanted hair growth, recovery of sexual function, preservation of bone health, or safe progression of puberty. Laboratory monitoring is most useful when tied to one of these clinical outcomes.
People using nonprescription “hormone balance” products should mention them before testing. DHEA, progesterone creams, testosterone boosters, compounded preparations, and biotin can alter physiology or make results harder to interpret. Product labels may not reliably predict the dose absorbed, so the safest approach is to review the exact container or ingredient list with the clinician.
Results can also differ because laboratories report conventional and SI units. A value expressed in ng/dL cannot be compared directly with one expressed in nmol/L without a hormone-specific conversion. Always compare the number, unit, and interval together. This simple check prevents many apparent contradictions between reports.
An abnormal result can have emotional weight, especially during fertility treatment, pregnancy, or puberty evaluation. Ask the clinician to separate what is known from what remains uncertain. A clear explanation of the likely causes, the confirmation plan, and the time frame for action is more useful than trying to interpret every decimal place independently.
Clinicians also consider whether the test result agrees with the physical findings. A marked biochemical abnormality without expected symptoms may prompt confirmation with a more specific laboratory method. Strong symptoms with a normal result may lead to testing at a different time, measuring a related hormone, or looking for a nonhormonal cause.
The pace of change can be as important as the level itself. Slow changes over years commonly fit physiologic aging or a chronic endocrine condition. Changes over weeks or a few months raise more concern for a new medicine effect, pregnancy-related change, acute illness, or a hormone-producing lesion, especially when symptoms progress quickly.
No single follow-up pathway fits every abnormal value. Mild and explainable results may only need observation. Persistent or substantial abnormalities may require specialist review and tests chosen to locate the source of hormone production or the level of signaling failure. The sequence should be deliberate so that each test answers a specific unresolved question.
Keep a copy of the laboratory report and the order indication. The clinician needs more than the highlighted flag: the numeric value, unit, reference interval, specimen type, collection date and time, and any comment about the assay can change interpretation. A result copied into a patient portal message without those details may be impossible to compare with a later test. This documentation is especially important when care moves between a primary clinician, endocrinologist, fertility clinic, and hospital laboratory.
Before repeating testing, decide what the repeat is meant to resolve. It may confirm persistence, correct a timing error, remove a medication effect, or use a more specific assay. Repeating the same poorly timed test without changing the conditions often reproduces uncertainty rather than solving it. The clinician should also state what result would lead to observation, another laboratory test, imaging, or treatment.
Small deviations from a reference interval are common because the interval usually contains about 95% of a selected comparison population. Some healthy people fall outside it, while some people with disease fall inside it. The clinical importance depends on how far the value is from the limit, whether it persists, whether related hormones agree, and whether symptoms fit the physiology. A reference flag is therefore a prompt for interpretation, not proof of disease.
Hormone results are also affected by changes in binding proteins and metabolism. Liver disease, thyroid disease, kidney disease, pregnancy, body composition, and oral estrogen exposure can change measured concentrations without producing the same change in tissue effect. When a binding issue is suspected, the clinician may use a free or calculated hormone, a related binding protein, or a more specific laboratory method rather than interpreting the total concentration alone.
Fertility decisions should not be reduced to a single endocrine value. A hormone may help choose medication dose, confirm ovulation, or identify a treatable disorder, but it does not measure every step required for pregnancy. Reproductive age, sperm exposure or semen quality, tubal patency, uterine anatomy, timing, prior pregnancies, and the duration of trying all influence the next step. A balanced evaluation prevents overreaction to an incidental result.
Testing can be different during pregnancy, adolescence, menopause, or hormone treatment because physiology is intentionally changing. A range derived from untreated adults may be inappropriate in these settings. Ask whether the laboratory interval matches the patient’s age and reproductive state and whether the clinical team uses a separate treatment or pregnancy target. This is particularly important when a portal automatically marks a result high or low against a generic range.
A laboratory method with greater analytical specificity is useful when the expected concentration is low, the result is surprising, or a major decision depends on the number. Mass-spectrometry methods can separate closely related steroids better than many immunoassays, while dynamic tests can reveal reserve or responsiveness that a basal sample cannot show. The best method depends on the hormone and question; a technically sophisticated test is not automatically necessary for every routine result.
Follow-up intervals should reflect the pace of the suspected condition. A stable borderline value may be repeated after a complete cycle, after recovery from illness, or after a treatment change reaches steady state. Rapidly progressive symptoms require days or weeks rather than months of observation. The plan should state both the routine follow-up date and the symptoms that justify contacting the clinician sooner.
References
- Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women 2025 (Guideline)
- Approach to androgen excess in women: Clinical and biochemical perspectives 2022 (Review)
- Recommendations for the measurement of sexual steroids in clinical practice. A position statement of SEQCML/SEEN/SEEP 2023 (Position Statement)
- Age- and sex-adjusted reference intervals for steroid hormones measured by liquid chromatography-tandem mass spectrometry using a widely available kit 2024 (Study)
- Congenital Adrenal Hyperplasia 2024 (Review)
Disclaimer
This article is general education and cannot diagnose PCOS, CAH, adrenal insufficiency, or an adrenal tumor. DHEA-S ranges depend strongly on age, sex, and method. Do not use DHEA or change steroid treatment without medical guidance.
